Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use XYNTHA safely and effectively. See full prescribing information for XYNTHA. XYNTHA® (antihemophilic factor [recombinant]) lyophilized powder for solution, for intravenous injection Initial U.S. Approval: 2008
Medication labelWhy this: Advisory · dailymed-other
XYNTHA, Antihemophilic Factor (Recombinant), is indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for: •On-demand treatment and control of bleeding episodes •Perioperative management •Routine prophylaxis to reduce the frequency of bleeding episodes XYNTHA does not contain von Willebrand factor, and therefore is not indicated in patients with von Willebrand's disease.
- generic_name
- antihemophilic factor (recombinant)
- brand_name
- diluent, alcohol
- product_names
- antihemophilic factor (recombinant), diluent, alcohol
- ndc
- 58394-012, 58394-013, 58394-014, 58394-015, 58394-012-01, 58394-112, 58394-112-01, 58394-018, 58394-018-01, 58394-013-01, 58394-113, 58394-113-01, 58394-014-01, 58394-114, 58394-114-01, 58394-015-01, 58394-115, 58394-115-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en